Feb 4 (Reuters) - Europe’s drugs regulator said on Thursday it will begin reviewing data on U.S. drugmakers Eli Lilly and Regeneron’s combination therapies of antibody-based treatments for use in COVID-19 patients.
Two separate reviews will be carried out to see if patients with COVID-19, who do not need oxygen support and are at high risk of their condition worsening, can be treated with these drugs, the European Medicines Agency said. (Reporting by Pushkala Aripaka in Bengaluru; Editing by Ramakrishnan M.)
我们的标准: 汤森路透“信任原则”